The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study
Open accessAbstract
Background and aims: The objective of this study was to evaluate the risk of colorectal cancer (CRC) in patients taking aminosalicylates (5-ASA) for inflammatory bowel disease (IBD). Methods: The General Practice Research Database (GPRD) which contains the primary care records of five million people in the UK was used to identify users of mesalazine, balsalazide, olsalazine, or sulfasalazine with a history of IBD. In a nested case control analysis, each incident CRC case with any use of a 5-ASA in the six months before the CRC diagnosis was matched by age, sex, and calendar time to six control patients who were also currently using a 5-ASA. Patients were then classified according to regularity of use. The analysis was controlled for body mass index, IBD duration, history of colorectal polyps, use of non-steroidal anti-inflammatory drugs, paracetamol, aspirin, immunosuppressants, oral and rectal glucocorticoids, prior gastrointestinal hospitalisation, recorded colonoscopy, and number of visits to the general practitioner for IBD symptoms in the 6–24 months before diagnosis. Results: The study population included 18 969 patients, of whom 100 had developed CRC during 5-ASA exposure. Most of these cases had a history of ulcerative colitis (76 patients). In the case control analysis, regular users, defined as having six or more 5-ASA prescriptions in the previous 12 months, were found to have a decreased risk of CRC compared with irregular users (crude odds ratio (OR) 0.7 (0.44–1.03); adjusted OR 0.60 (0.38–0.96)). Regular users of sulfasalazine with 6–12 prescriptions before had an adjusted OR of 0.95 (0.22–4.11); with 13–30 prior prescriptions this was 0.41 (0.14–1.20) and with >30 prior prescriptions this was 0.77 (0.37–1.60). For mesalazine users, these values were 1.13 (0.49–2.59), 0.30 (0.11–0.83), and 0.31 (0.11–0.84), respectively. Conclusion: These results show that regular 5-ASA use is associated with some reduction in the risk of CRC developing in ulcerative colitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., Williams, C., Price, A., Talbot, I., & Forbes, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.010 · Cited by 1,255
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J. F., Kliewer, E., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z · Cited by 1,165
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021633 · Cited by 1,136
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 623
Colorectal cancer prevention in ulcerative colitis: a case‐control study
Eaden, Abrams, Ekbom, Jackson, & Mayberry (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00698.x · Cited by 577
Velayos, F. S., Loftus, E. V., Jess, T., Harmsen, W. S., Bida, J., Zinsmeister, A. R., Tremaine, W. J., & Sandborn, W. J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.028 · Cited by 399
Benamouzig, R., Deyra, J., Martin, A., Girard, B., Jullian, E., Piednoir, B., Couturier, D., Coste, T., Little, J., & Chaussade, S. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00887-4 · Cited by 395
Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study
Pinczowski, D., Ekbom, A., Baron, J., Yuen, J., & Adami, H.-O. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90068-x · Cited by 337
Lashner, B. A., Heidenreich, P. A., Su, G. L., Kane, S. V., & Hanauer, S. B. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90058-9 · Cited by 319
Inflammatory bowel disease: epidemiology and management in an English general practice population
Rubin, G. P., Hungin, A. P. S., Kelly, P. J., & Ling, J. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00886.x · Cited by 315
Inflammatory bowel disease and the risk of fracture
Van staa, T.-P., Cooper, C., Samuels Brusse, L., Leufkens, H., Javaid, M. K., & Arden, N. K. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.027 · Cited by 245
Self-citationMoody, G. A., Jayanthi, V, Probert, C. S. J., Kay, H. M., & Mayberry, J. F. (1996) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199612000-00009 · Cited by 240
Lewis, J. D., Brensinger, C., Bilker, W. B., & Strom, B. L. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.698 · Cited by 189
Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas
Huls, G. A., Koornstra, J. J., & KLEIBEUKER, J. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13915-3 · Cited by 140
van Staa, T. P., & Abenhaim, L. (1994) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2630030106 · Cited by 138
Lindberg, B. U., Broomé, U., & Persson, B. (2001) · Diseases of the Colon & Rectum · doi:10.1007/bf02234825 · Cited by 120
Bernstein, C. N., Blanchard, J., Metge, C. J., & Yogendran, M. S. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.08718.x · Cited by 111
Eaden, J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.18.s2.3.x · Cited by 99
Reinacher-Schick, A. C., Seidensticker, F., Petrasch, S., Reiser, M., Philippou, S., Theegarten, D., Freitag, G., & Schmiegel, W. (2000) · Endoscopy · doi:10.1055/s-2000-135 · Cited by 95
Bernstein, C. N., Eaden, J., Steinhart, A. H., Munkholm, P. S., & Gordon, P. H. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200209000-00007 · Cited by 67
Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow
Ryan, B. M., Rüssel, M. G., Langholz, E., & Stockbrügger, R. W. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00450-7 · Cited by 45
Cited by
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Stange, E. F., Travis, S. P. L., Vermeire, S., Reinisch, W., Geboes, K., Barakauskiene, A., Feakins, R., Fléjou, J. F., Herfarth, H., Hommes, D. W., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.001 · Cited by 555
Farraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.035 · Cited by 494
Van Assche, G., Dignass, A., Bokemeyer, B., Danese, S., Gionchetti, P., Moser, G., Beaugerie, L., Gomollón, F., Häuser, W., Herrlinger, K., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.005 · Cited by 463
Metadata
- Authors
- van Staa, T. P., Card, T., Logan, R. F., & Leufkens, H. G. M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-06-30
- Volume
- 54
- Issue
- 11
- Pages
- 1573-1578
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W1882497657
- Cited by
- 287
- References
- 23
- FWCI
- 11.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.